Good problems to have? Policy and societal implications of a disease-modifying therapy for presymptomatic late-onset Alzheimer’s disease
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2195-7819
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Good problems to have? Policy and societal implications of a disease-modifying therapy for presymptomatic late-onset Alzheimer’s disease ; volume:16 ; number:1 ; day:12 ; month:10 ; year:2020 ; pages:1-11 ; date:12.2020
Life sciences, society and policy ; 16, Heft 1 (12.10.2020), 1-11, 12.2020
- Urheber
-
Angrist, Misha
Yang, Anna
Kantor, Boris
Chiba-Falek, Ornit
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s40504-020-00106-2
- URN
-
urn:nbn:de:101:1-2020111219325099294661
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:33 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Angrist, Misha
- Yang, Anna
- Kantor, Boris
- Chiba-Falek, Ornit
- SpringerLink (Online service)
Ähnliche Objekte (12)
Disease-modifying treatments in Alzheimer’s disease
Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
Alzheimer’s Disease (AD) Detect & Prevent : presymptomatic AD detection and prevention
Identifying genetic interactions associated with late-onset Alzheimer’s disease
Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer’s disease
Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease
Genetic data and cognitively defined late-onset Alzheimer’s disease subgroups
Early and late-onset Alzheimer’s disease: What are the differences?
The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease
Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease
A retrotransposon storm marks clinical phenoconversion to late-onset Alzheimer’s disease
Disease-modifying treatments in Alzheimer’s disease
Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
Alzheimer’s Disease (AD) Detect & Prevent : presymptomatic AD detection and prevention
Identifying genetic interactions associated with late-onset Alzheimer’s disease
Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer’s disease
Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease
Genetic data and cognitively defined late-onset Alzheimer’s disease subgroups
Early and late-onset Alzheimer’s disease: What are the differences?
The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease
Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease
A retrotransposon storm marks clinical phenoconversion to late-onset Alzheimer’s disease
Disease-modifying treatments in Alzheimer’s disease
Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
Alzheimer’s Disease (AD) Detect & Prevent : presymptomatic AD detection and prevention
Identifying genetic interactions associated with late-onset Alzheimer’s disease
Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer’s disease
Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease
Genetic data and cognitively defined late-onset Alzheimer’s disease subgroups
Early and late-onset Alzheimer’s disease: What are the differences?
The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease
Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease